Case Based Roundtable Logo

This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.

Chemotherapy Utilized in Pretreated Metastatic Castration-Resistant Prostate Cancer

Safety Results with Cabazitaxel Support Wider Use in mCRPC
Safety Results with Cabazitaxel Support Wider Use in mCRPC
September 08, 2023
In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.
Considerations on Tolerability of Cabazitaxel in mCRPC
December 16, 2022
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
November 30, 2022
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Identifying Which Patients Benefit From Cabazitaxel for mCRPC
Identifying Which Patients Benefit From Cabazitaxel for mCRPC
October 07, 2022
During a live virtual event, Edwin M. Posadas, MD, discussed the use of cabazitaxel in patients with metastatic castration-resistant prostate cancer with participants. This is the second of 2 articles based on this event.
PSMA-Targeted Treatment Considered in mCRPC After AR Inhibition
PSMA-Targeted Treatment Considered in mCRPC After AR Inhibition
August 10, 2022
During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 05, 2022
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
June 15, 2022
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.